Skip to main content
Unchecking box will stop auto data updates
TSX Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 12.24
Day High 12.42
Open:12.25
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Trailing Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Fennec Announces Publication of Pedmark(TM) Siopel 6 Clinical Data in the New England Journal of Medicine
GlobeNewswire - Thu Jun 21, 5:00AM CDT
GlobeNewswire - CMTX
Thu Jun 21, 5:00AM CDT
-- SIOPEL 6 met primary endpoint (p=0.002)
Today's Research Reports on Fennec Pharmaceuticals, ProMIS Neurosciences, Theratechnologies and Cipher Pharmaceuticals
ACCESSWIRE - Wed Jun 13, 7:03AM CDT
ACCESSWIRE - CMTX
Wed Jun 13, 7:03AM CDT
NEW YORK, NY / ACCESSWIRE / June 13, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at and get exclusive access to our numerous research reports and market updates.
Fennec Pharmaceuticals Set to Join Russell 3000 Index
GlobeNewswire - Mon Jun 11, 5:00AM CDT
GlobeNewswire - CMTX
Mon Jun 11, 5:00AM CDT
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARK (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, announced today it is set to join the broad-market Russell 3000Index at the conclusion of the Russell US Indexes annual reconstitution, effective after the US market opens on June 25, according to a preliminary list of additions posted June 8.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 12.24 unch no change
on 07/18/18
Period Open:14.29
Price movement based on the high, low and last over the given period.
15.62 -21.64% decrease
on 06/25/18
-2.05 (-14.35%) decrease
since 06/18/18
3-Month 12.24 unch no change
on 07/18/18
Period Open:17.35
Price movement based on the high, low and last over the given period.
17.25 -29.04% decrease
on 04/24/18
-5.11 (-29.45%) decrease
since 04/18/18
52-Week 7.10 +72.39% increase
on 07/28/17
Period Open:8.79
Price movement based on the high, low and last over the given period.
18.86 -35.10% decrease
on 04/09/18
+3.45 (+39.25%) increase
since 07/18/17

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2018.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

More stories below advertisement